A pharma veteran looking for new ways to discover effective treatments for CNS diseases such as depression & Alzheimer's disease. These opinions are my own.
Exciting news - we're recruiting to a study into early Alzheimer's disease which is using the latest scanning technology. Thanks to the New Therapeutics in Alzheimer's Disease study team @OxDARE @EKocagoncu @JemmyPitt@CambridgeFTD@OHBA_Oxford
https://t.co/LOYLuppOP9
As the coronavirus outbreak worsens, #JNJ has mobilized quickly to develop a potential preventive vaccine for the virus. Learn how J&J scientists are leveraging innovative vaccine technologies & global partnerships to help meet the needs of this outbreak: https://t.co/Tsswf5OUAv
The coronavirus emergence in Wuhan, China has turned into an outbreak with almost 3,000 confirmed cases, according to @WHO. Learn how #JNJ has mobilized to help develop a potential preventive vaccine as part of our commitment to fight emerging epidemics: https://t.co/Tsswf5OUAv
$JNJ Chief Scientific Officer Dr Paul Stoffels told us this AM on @SquawkCNBC the co started working on #coronavirus vaccine 2 wks ago https://t.co/FYGaUmIewf
In choosing to donate his brain to @UCL brain bank #TerryJones made an important contribution to #research and the rare form of #dementia he lived with https://t.co/eY53PygNvg
Following the recent Coronavirus emergence in Wuhan, China, Paul Stoffels, Vice Chairman of the Executive Committee & CSO, #JNJ, details how J&J and its partners are working to mobilize our best scientists to investigate how we can make a difference. Watch to learn more. #WEF20
Paul Stoffels @JNJNews CSO tells @BBCr4today that company already has candidate vaccine for coronavirus at lab stage & will move into clinic within months while reassuring listeners that other #pharma industries are stepping up to develop vaccines & therapeutics
Our newest #partnership with significantly expands Janssen R&D’s Retinal portfolio, bringing us one step closer to advancing new and potentially breakthrough therapies for people living with retinal disorders. Learn more here: https://t.co/1MH7paE5A4
👀Sight – it’s the sense most people say they fear losing. What if sight-saving medicines could be made into a simpler form, one that would be easier to use? @ExonateUK is teaming up with @JanssenGlobal ⬇️ #JPM20
#Australia#bushfires : How to donate, support firefighters & wildlife. So far 6.3M hectares (16M acres)burned, more than California & Amazon fires combined. This is home to thousands of people & millions of animals. Please give generously. 🙏🏻🇦🇺 🦘 🐨 https://t.co/q2jEHDPFLw
Day 173 of Christmas. We try sending a rescue message to loved ones using Maltesers. It is both a success and a failure in equal measures. https://t.co/kZcXjhLJOZ
.@CRiverLabs and @Evotec will work closely and collaboratively with the, academic researchers who are successful in securing project #funding from the Psychiatry Consortium– read more > https://t.co/aO2RfnNVRM
The expertise and capabilities of @CRiverLabs and @Evotec will complement those of the academic researchers funded by the Psychiatry Consortium to advance innovative and impactful #drugdiscovery projects in psychiatric diseases – find out more > https://t.co/PJ7LBwDQcF